公开(公告)号：US11721021B2

公开(公告)日：2023-08-08

申请号：US17895221

申请日：2022-08-25

Applicant: Wisconsin Alumni Research Foundation ,  The Medical College of Wisconsin, Inc.

Inventor： David Frazier Jarrard ,  Bing Yang ,  Peter LaViolette

IPC: G06T7/00 ,  G16H30/40 ,  G16H50/30 ,  G01N1/30

CPC classification number: G06T7/0012 ,  G01N1/30 ,  G16H30/40 ,  G16H50/30 ,  G01N2001/302 ,  G01N2001/305

Abstract: A method of detecting the presence of a prostate cancer in a human subject comprising the steps of (a) obtaining a histologically normal prostate tissue sample from the patient and (b) quantifying the epithelial thickness or gland lumen roundness of the tissue, wherein an increase in epithelial thickness or a decrease in gland lumen roundness indicates the presence of prostate cancer or a prostate cancer field defect.

公开(公告)号：US11377694B2

公开(公告)日：2022-07-05

申请号：US15970235

申请日：2018-05-03

Applicant: Wisconsin Alumni Research Foundation

Inventor： David Frazier Jarrard ,  Bing Yang

IPC: C12Q1/6886

Abstract: A method of detecting the presence of a prostate cancer field defect in a human subject comprising the step of (a) obtaining genomic DNA from the human subject and (b) quantitating methylation in at least one target region selected from the group consisting of CAV1, EVX1, MCF2L, FGF1, NCR2 and WNT2 and EXT1 and SPAG4 target, wherein significant methylation changes indicate the presence of prostate cancer or a prostate cancer field defect, wherein the change is relative to tissue from a second human subject who does not have prostate cancer.

公开(公告)号：US12252747B2

公开(公告)日：2025-03-18

申请号：US17837731

申请日：2022-06-10

Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION

Inventor： David Frazier Jarrard ,  Bing Yang

IPC: C12Q1/6886

Abstract: A method of detecting the presence of a prostate cancer field defect in a human subject comprising the step of (a) obtaining genomic DNA from the human subject and (b) quantitating methylation in at least one target region selected from the group consisting of CAV1, EVX1, MCF2L, FGF1, NCR2 and WNT2 and EXT1 and SPAG4 target, wherein significant methylation changes indicate the presence of prostate cancer or a prostate cancer field defect, wherein the change is relative to tissue from a second human subject who does not have prostate cancer.

公开(公告)号：US11130998B2

公开(公告)日：2021-09-28

申请号：US15811876

申请日：2017-11-14

Applicant: Wisconsin Alumni Research Foundation

Inventor： David Frazier Jarrard ,  Bing Yang

IPC: C12Q1/68 ,  C12Q1/6886 ,  C12Q1/6853 ,  C12Q1/6806 ,  C12Q1/686

Abstract: A method of detecting the presence of a prostate cancer field defect in a human subject comprising the step of (a) obtaining genomic DNA from the human subject and (b) quantitating methylation in at least one target region selected from the group consisting of PLA2G16, CAV1, EVX1, MCF2L, FGF1, NCR2 and WNT2 and EXT1 and SPAG4 target, wherein significant methylation changes indicate the presence of prostate cancer or a prostate cancer field defect, wherein the change is relative to tissue from a second human subject who does not have prostate cancer.

公开(公告)号：US10598664B2

公开(公告)日：2020-03-24

申请号：US15812015

申请日：2017-11-14

Applicant: Wisconsin Alumni Research Foundation

Inventor： David Frazier Jarrard ,  Bing Yang

IPC: G01N33/574 ,  G06K9/00 ,  G06T7/00

Abstract: A method of detecting the presence of a prostate cancer in a human subject comprising the steps of (a) obtaining a histologically normal prostate tissue sample from the patient and (b) quantifying the epithelial percentage of the tissue, wherein an epithelial percentage greater than 39% indicates the presence of prostate cancer or a prostate cancer field defect.